We moved the contents of this article into Ten Steps to a Winning R01 Application. As part of the Strategy for NIH Funding, the ten steps give you a path to funding success if you're applying for an R01.
Hollywood will honor the best of the best next month at the Oscars, but NIH has already chosen the 2011 winners of "outstanding junior scientists in a leading role."
Their prize: an NIH Director's Early Independence Award (EIA), which matches exceptionally creative, mature, and productive young scientists with a host institution.
As the first to receive EIAs, the 10 investigators—including NIAID grantee Dr. Nicole E. Basta at the University of Washington—are getting a lot of attention.
Not only were they in Bethesda last month for an inaugural kickoff meeting with NIH Director Dr. Francis Collins, but they're also featured in a new NIH brochure and video.
Read NIH Director's Early Independence Award (EIA)—A Grand Experiment in Catalyzing the Biomedical Workforce for a brief description of the awards and awardees, and watch the 2011 NIH Early Independence Award Scientists video to hear recipients' thoughts on the benefits of EIAs.
Five of the awardees are also in the spotlight outside NIH. They made Forbes Magazine's 30 Under 30, a list of 30 people under the age of 30 who are considered to be tomorrow’s brightest stars in several categories, including Science and Innovation.
Their appearance on the list speaks to how exceptional a junior investigator you must be to receive an EIA. We touched on this in our December 7, 2011, article "Gain Early Independence With NIH Director's Award." We also mentioned that the deadline for applications is January 30, so keep that in mind if you plan to submit.
EIAs are part of the High Risk-High Reward program of the NIH Common Fund, which encourages collaboration and supports a series of exceptionally high impact, trans-NIH programs. Find additional information at The NIH Common Fund.
We just announced our actual (non-interim) FY 2012 paylines at 10 percentile for non-new PIs and 14 for new PIs.
Unlike the other paylines, we maintain our R01 paylines until the end of the fiscal year.
The remaining paylines are interim. We still do not have a payline for institutional training grants (T32).
See the full list at NIAID Paylines.
Following up on the January 4, 2012, article "Changing of the Guard for DEA," we are pleased to announce the selection of Dr. Matthew Fenton as acting director of the Division of Extramural Activities.
Dr. Fenton is a familiar face to many of you in his former role as chief of the Allergy, Asthma, and Airway Biology Branch in the Division of Allergy, Immunology and Transplantation.
Working in that position for seven years, he oversaw NIAID-supported research of asthma, allergic diseases, and related immune-mediated diseases, focusing on initiatives to promote the translation of basic research findings into clinical trials.
For example, Dr. Fenton helped lead the effort to assess the safety and efficacy of a novel monovalent 2009 pandemic influenza vaccine in asthmatics, resulting in the first clinical trial to evaluate the immune response of severe asthmatics to an influenza vaccine.
He also chaired a broad-based group that created the Clinical Guidelines for the Diagnosis and Management of Food Allergy in the United States.
In addition to authoring over 100 peer-reviewed publications, Dr. Fenton has chaired peer review study sections, served as section editor of the Journal of Immunology, and held the position of president for both the International Cytokine Society and Society for Leukocyte Biology.
Before joining NIAID, Dr. Fenton was a tenured professor of medicine, immunology and microbiology at the University of Maryland School of Medicine in Baltimore and a professor of medicine and pathology at the Boston University School of Medicine.
He received his Ph.D. in biochemistry from Boston University in 1984 and was a postdoc at the Massachusetts Institute of Technology from 1984 to 1988.
Before your calendar fills up, leave room for a workshop on applying for clinical trials units (CTUs) for NIAID's clinical research networks. A funding opportunity announcement for the CTUs is expected to be out this spring.
To help applicants navigate the application and review process, the Institute will hold three workshops, the first of which is scheduled for July 28 and 29 in Washington, D.C., immediately following the International AIDS Society’s XIX International AIDS Conference (“AIDS 2012”).
We don't yet have dates for the other two workshops, but we do have the locations: South America and Africa.
Come spring, you'll find additional information, including registration instructions, at Restructuring the NIAID Clinical Trials Networks.
Here's news from around NIH.
Business as Usual for Reauthorized Small Business Programs—For Now. Though NIH's small business programs were reauthorized on December 31 as part of H.R. 1540, we don't expect to get the final rules for months. Until then, our existing policies continue.
Reminder: Annual Report on Laboratory Animals. Your calendar year 2011 report is due from your institution by January 31, 2012. See Annual Report to OLAW for instructions and a sample.
If you’re looking for funding beyond the NIAID Funding Opportunities List, take a moment to review NIAID's List of Foundations and Other Funding Sources.
You'll find links to independent research grants, fellowships, training opportunities, and other types of support offered by organizations outside NIH.
We cull the list to make sure it’s up-to-date and features organizations and opportunities within NIAID’s research areas.
If you'd like to suggest a foundation to add, please email email@example.com. Our list is intended solely as a service to the community and we don't endorse any organization.
Feel free to send us a question at firstname.lastname@example.org. After responding to you, we may include your question in the newsletter, incorporate it into the NIAID Research Funding site, or both.
"We are preparing a multiproject application where one core is using animals to generate cell lines that will be used by the five projects. On the Face Page, which sections should be Yes for Vertebrate Animals?"—Jacqueline Arciniega, NYU Langone Medical Center
The overall program and each project using vertebrate animals need a Vertebrate Animals section, unless any project is using the cell lines only. On the face page, indicate Yes for vertebrate animals.
The administrative core does not need a Vertebrate Animals section. Basically, any part of the application that uses animals must have a Vertebrate Animals section, otherwise it will receive a bar to award.
See these and older announcements at NIAID Funding Opportunities List.
back to top
Last Updated February 27, 2012
Last Reviewed January 18, 2012